The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

EC approves Ordspono to treat r/r FL or r/r DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The European Commission approved Ordspono (odronextamab) to treat adult patients with relapsed or refractory follicular lymphoma or r/r diffuse large B-cell lymphoma, after two or more lines of systemic therapy. Ordspono is a bispecific antibody that acts by linking the lymphoma cell to a killer T cell.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account